Sanofi's blockbuster drug Dupixent has been approved in Europe to treat pulmonary diseases.

Zhītōng Cáijīng APP learned that sanofi (SNY.US) heavyweight drug Dupixent has been approved for use in European patients with chronic lung disease, opening up a new path of growth. According to a statement from the company on Wednesday, European regulators became the first in the world to approve the vaccine as an additional treatment for patients with chronic obstructive pulmonary disease (some with high levels of white blood cells). In two milestone studies, the drug reduced disease progression, improved lung function, and improved quality of life. The decision makes Dupixent a treatment option for approximately 220,000 adult CO patients in the European Union.

Zhitong FinanceJul 3 14:53

Kamada Draws Buy at Stifel on Underappreciated Potential

Seeking Alpha00:59

Sanofi CEO Says Talking To Private Equity For Sale Of Consumer Arm

Sanofi CEO Says Talking To Private Equity For Sale Of Consumer Arm

BenzingaJul 3 23:59

Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division, Bloomberg Reports

Sanofi (SNY) Price: 48.79, Change: +0.24, Percent Change: +0.50

MT NewswiresJul 3 23:29

GSK Will Pay Up to $1.5 Billion for CureVac's MRNA Vaccines -- Barrons.com

By Josh Nathan-Kazis The drugmaker GSK plunged into the messenger RNA-based vaccine market Wednesday, announcing it will buy the rights to experimental influenza and Covid-19 mRNA vaccines from the b

Barron'sJul 3 22:18

Argus Research Maintains Sanofi(SNY.US) With Buy Rating, Cuts Target Price to $55

Argus Research analyst Jasper Hellweg maintains $Sanofi(SNY.US)$ with a buy rating, and adjusts the target price from $60 to $55.According to TipRanks data, the analyst has a success rate of 58.9% and

Futu NewsJul 3 21:32 · Ratings